Bliss GVS Pharma Ltd
NSE:BLISSGVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bliss GVS Pharma Ltd
Cash from Operating Activities
Bliss GVS Pharma Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bliss GVS Pharma Ltd
NSE:BLISSGVS
|
Cash from Operating Activities
₹1.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹58.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹42.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹127.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Operating Activities
₹47.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Operating Activities
₹19.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Bliss GVS Pharma Ltd
Glance View
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 750 full-time employees. The company went IPO on 2010-07-26. The firm offers a range of suppositories, tablets, suspensions and injections to various therapeutic segments, including antimalarial, antifungal, dermatological, contraceptive, laxative, anti-hemorrhoidal, antispasmodic, antibiotic, antimicrobial antipyretic, analgesic and anti-inflammatory. The firm's pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatin capsules and syrups. its other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray and petroleum jelly. The firm offers its products under various brands, which include Lonart, Funbact, P-Alaxin, Lofnac, Amoxicillin, Antiderm Extra Plus and Esmazole. Its product portfolio comprises over 250 branded formulations across 20 therapeutic segments.
See Also
What is Bliss GVS Pharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.4B
INR
Based on the financial report for Dec 31, 2025, Bliss GVS Pharma Ltd's Cash from Operating Activities amounts to 1.4B INR.
What is Bliss GVS Pharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
8%
Over the last year, the Cash from Operating Activities growth was 29%.
